Family Practice Vol. 20, No. 1, 61-68
© Oxford University Press 2003
Clinical Research |
Influences on GPs’ decision to prescribe new drugs—the importance of who says what
Prescribing Research Group, Department of Pharmacology and Therapeutics, The Infirmary, 70 Pembroke Place, Liverpool L69 3GF and
a Royal Liverpool University Hospital, Liverpool L7 8XP, UK.
Correspondence to Helen Prosser; E-mail: H.Prosser{at}liverpool.ac.uk
Objectives. The aim of this study was to understand the range of factors that influence GPs’ uptake of new drugs
Methods. A total of 107 GPs selected purposively from high, medium and low new drug prescribing practices in two health authorities in the north west of England were interviewed using the critical incident technique with semi-structured interviews. Interview topics included reasons for prescribing new drugs launched between January 1998 and May 1999; reasons for prescribing the new drug rather than alternatives; and sources of information used for each prescribed drug.
Results. Important biomedical influences were the failure of current therapy and adverse effect profile. More influential than these, however, was the pharmaceutical representative. Hospital consultants and observation of hospital prescribing was cited next most frequently. Patient request for a drug, and patient convenience and acceptability were also likely to influence new drug uptake. Written information was of limited importance except for local guidelines. GPs were largely reactive and opportunistic recipients of new drug information, rarely reporting an active information search. The decision to initiate a new drug is heavily influenced by ‘who says what’, in particular the pharmaceutical industry, hospital consultants and patients. The decision to ‘adopt’ a new drug is clinched by subsequent personal clinical experience.
Conclusions. Prescribing of new drugs is not simply related to biomedical evaluation and critical appraisal but, more importantly, to the mode of exposure to pharmacological information and social influences on decision making. Viewed within this broad context, prescribing variation becomes more understandable. Findings have implications for the implementation of evidence-based medicine, which requires a multifaceted approach.
Keywords. General practice, information sources, prescribing influences, prescription drugs.
CiteULike 
Connotea 
Del.icio.us What's this?
This article has been cited by other articles:
|
|
 |
|
  J. Avorn and N. K. Choudhry Funding for Medical Education: Maintaining a Healthy Separation From Industry Circulation, May 25, 2010; 121(20): 2228 - 2234. [Full Text] [PDF]
|
|
|
|
 |
|
 J.E. Thistlethwaite, R. Ajjawi, and P. Aslani The decision to prescribe: influences and choice InnovAiT, April 1, 2010; 3(4): 237 - 243. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 H. Prosser Marvelous medicines and dangerous drugs: the representation of prescription medicine in the UK newsprint media Public Understanding of Science, January 1, 2010; 19(1): 52 - 69. [Abstract] [PDF]
|
|
|
|
 |
|
 P. J Lewis and M. P Tully Uncomfortable prescribing decisions in hospitals: the impact of teamwork J R Soc Med, November 1, 2009; 102(11): 481 - 488. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. Stremersch and A. Lemmens Sales Growth of New Pharmaceuticals Across the Globe: The Role of Regulatory Regimes Marketing Science, July 1, 2009; 28(4): 690 - 708. [Abstract] [PDF]
|
|
|
|
 |
|
 M. Carey, H. Buchan, and R. Sanson-Fisher The cycle of change: implementing best-evidence clinical practice Int. J. Qual. Health Care, February 1, 2009; 21(1): 37 - 43. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 T. J Steiner Ethical Issues Arising from Commercial Sponsorship and from Relationships with the Pharmaceutical Industry--Report and Recommendations of the Ethics Subcommittee of the International Headache Society Cephalalgia, September 1, 2008; 28(3_suppl): 1 - 25. [Full Text] [PDF]
|
|
|
|
 |
|
 S. R Florentinus, R. van Hulten, M. E. Kloth, E. R Heerdink, A. F. Griens, H. G. Leufkens, P. P Groenewegen, and for the Netherlands Institute for Health Services The Effect of Pharmacotherapy Audit Meetings on Early New Drug Prescribing by General Practitioners Ann. Pharmacother., February 1, 2007; 41(2): 319 - 324. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M A Morgan, J Dana, G Loewenstein, S Zinberg, and J Schulkin Interactions of doctors with the pharmaceutical industry. J. Med. Ethics, October 1, 2006; 32(10): 559 - 563. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 What Is Safe Enough? DOC News, September 1, 2006; 3(9): 12 - 12. [Full Text]
|
|
|
|
 |
|
 A. Kapmeyer, C. Meyer, M. M Kochen, and W. Himmel Doctors' strategies in prescribing drugs: the case of mood-modifying medicines Fam. Pract., February 1, 2006; 23(1): 73 - 79. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 F A Knox, M Barry, B McGowan, and C O'Brien The rising cost of glaucoma drugs in Ireland 1996-2003 Br J Ophthalmol, February 1, 2006; 90(2): 162 - 165. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
P. E. Muijrers, R. P. Grol, J. Sijbrandij, R. Janknegt, and J A. Knottnerus Differences in prescribing between GPs. Impact of the cooperation with pharmacists and impact of visits from pharmaceutical industry representatives Fam. Pract., December 1, 2005; 22(6): 624 - 630. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 F. S. Sierles, A. C. Brodkey, L. M. Cleary, F. A. McCurdy, M. Mintz, J. Frank, D. J. Lynn, J. Chao, B. Z. Morgenstern, W. Shore, et al. Medical Students' Exposure to and Attitudes About Drug Company Interactions: A National Survey JAMA, September 7, 2005; 294(9): 1034 - 1042. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. C. Brodkey The Role of the Pharmaceutical Industry in Teaching Psychopharmacology: A Growing Problem Acad Psychiatry, June 1, 2005; 29(2): 222 - 229. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. F Shaughnessy and D. C Slawson Research was evidence based BMJ, October 4, 2003; 327(7418): 811 - 811. [Full Text]
|
|
|
|
|
|
H. Prosser and T. Walley New drug uptake: qualitative comparison of high and low prescribing GPs' attitudes and approach Fam. Pract., October 1, 2003; 20(5): 583 - 591. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 K. T. Bain, D. J. Weschules, C. H. Knowlton, and R. Gallagher Toward evidence-based prescribing at end of life: A comparative review of temazepam and zolpidem for the treatment of insomnia American Journal of Hospice and Palliative Medicine, September 1, 2003; 20(5): 382 - 388. [Abstract] [PDF]
|
|
|
|
|
|
M. Lagnado and S. Kohll Seven steps to evidence based general practice BMJ, April 26, 2003; 326(7395): 933 - 933. [Full Text]
|
|
|
|
|
|
R. Dobson Pharmaceutical industry is main influence in GP prescribing BMJ, February 8, 2003; 326(7384): 301 - 301. [Full Text] [PDF]
|
|